We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.

A phase 1 program including three separate studies have been completed during the autumn in 2020. Read more hear about the clinical development of ROSgard.

Read more

CLINICAL STUDIES

ROSgard, our drug candidate, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

ROSgard™

Acute kidney injury is a large market. The estimated annual value is USD 6.3 bn in the USA and GBP 500 mn in the UK.

Read more

INVESTOR RELATIONS

Press releases
  • 17 Jun 2021

    Last patient recruited to Guard Therapeutics’ phase 1b study of the investigational drug ROSgard

    Read more
  • 31 May 2021

    Guard Therapeutics establishes a scientific committee with prominent international physicians and researchers in cardiothoracic surgery, intensive care and nephrology

    Read more
  • 09 Apr 2021  ·  Regulatory information

    Guard Therapeutics receives an Intention to Grant notice in Europe for ROSgard

    Read more
  • 07 Apr 2021

    Guard Therapeutics obtains a granted patent from USPTO concerning ROSgard as product

    Read more
Show more
Calendar & reports
  • 19 Aug 2021

    Interim report April-June 2021

    Read more
  • 18 Nov 2021

    Interim report July-September 2021

    Read more
  • 22 Feb 2022

    Year-end report 2021

    Read more
Reports, presentations & in media
  • 31 May 2021 / Presentation

    Biostock

    Read more
  • 01 Feb 2021 / In media

    (in Swedish) Rutger Arnhults och EQT-veteranens läkemedelsbolag får tyskt klartecken

    Read more
  • 04 Jun 2020 / Analysis

    Monocl valuation report for cardiac surgery AKI 2018

    Read more
  • 04 Jun 2020 / Analysis

    Redeye valuation report 2019

    Read more
Show more